CN101903040A - 含有禽流感基因的火鸡疱疹病毒载体重组体 - Google Patents

含有禽流感基因的火鸡疱疹病毒载体重组体 Download PDF

Info

Publication number
CN101903040A
CN101903040A CN2008800166743A CN200880016674A CN101903040A CN 101903040 A CN101903040 A CN 101903040A CN 2008800166743 A CN2008800166743 A CN 2008800166743A CN 200880016674 A CN200880016674 A CN 200880016674A CN 101903040 A CN101903040 A CN 101903040A
Authority
CN
China
Prior art keywords
asn
leu
ser
glu
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008800166743A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂·M·多尔西
劳伦·E·詹森
江崎素之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceva Sante Animale SA
Original Assignee
Ceva Sante Animale SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale SA filed Critical Ceva Sante Animale SA
Publication of CN101903040A publication Critical patent/CN101903040A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16441—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2008800166743A 2007-03-30 2008-03-28 含有禽流感基因的火鸡疱疹病毒载体重组体 Pending CN101903040A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/729,978 2007-03-30
US11/729,978 US20080241188A1 (en) 2007-03-30 2007-03-30 Turkey herpesvirus vectored recombinant containing avian influenza genes
PCT/US2008/004070 WO2008121329A2 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes

Publications (1)

Publication Number Publication Date
CN101903040A true CN101903040A (zh) 2010-12-01

Family

ID=39794757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800166743A Pending CN101903040A (zh) 2007-03-30 2008-03-28 含有禽流感基因的火鸡疱疹病毒载体重组体

Country Status (7)

Country Link
US (4) US20080241188A1 (enExample)
EP (1) EP2129390B1 (enExample)
JP (1) JP5508252B2 (enExample)
CN (1) CN101903040A (enExample)
ES (1) ES2399845T3 (enExample)
PL (1) PL2129390T3 (enExample)
WO (1) WO2008121329A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103740759A (zh) * 2014-01-20 2014-04-23 中国农业科学院哈尔滨兽医研究所 表达h5n1亚型禽流感病毒ha基因的重组火鸡疱疹病毒
CN106399267A (zh) * 2016-10-28 2017-02-15 扬州大学 表达H7N9亚型禽流感病毒血凝素蛋白的重组火鸡疱疹病毒株rHOH及构建方法
CN106497893A (zh) * 2016-10-28 2017-03-15 扬州大学 表达H7N9亚型禽流感病毒嵌合型血凝素蛋白的重组火鸡疱疹病毒株rHMW及构建方法
CN109402071A (zh) * 2018-11-08 2019-03-01 中国农业大学 一种表达h9n2亚型禽流感病毒h9蛋白的重组火鸡疱疹病毒
CN111733143A (zh) * 2012-03-30 2020-10-02 法国诗华动物保健公司 多价重组禽疱疹病毒和用于免疫禽类的疫苗
CN114184797A (zh) * 2021-12-06 2022-03-15 辽宁成大生物股份有限公司 一种流感病毒裂解疫苗单价原液血凝素的检测方法
WO2025180501A1 (en) * 2024-02-29 2025-09-04 Ceva Animal Health Technology (Hangzhou) Co., Ltd. Recombinant hvt and uses thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140557A2 (en) 2006-10-24 2008-11-20 Samuel Bogoch A method of predicting influenza outbreaks
WO2008156914A2 (en) 2007-05-30 2008-12-24 Samuel Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
BRPI0913216A2 (pt) * 2008-06-23 2016-01-19 Intervet Int Bv uso de um herpesvírus recombinante de perus, e, herpesvírus recombinante de perus.
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
WO2010119112A1 (en) 2009-04-15 2010-10-21 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
CA2759325A1 (en) * 2009-04-23 2010-10-28 Samuel Bogoch Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
US9320784B2 (en) 2009-08-07 2016-04-26 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
EP2629794B1 (en) * 2010-10-18 2017-06-07 Intervet International B.V. Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
US10179229B2 (en) 2014-12-23 2019-01-15 Edge Systems Llc Devices and methods for treating the skin using a porous member
PL3471766T3 (pl) 2016-06-17 2023-04-11 Intervet International B.V. Rekombinowane konstrukty niepatogennego wirusa choroby Mareka kodujące antygeny wirusa zakaźnego zapalenia krtani i tchawicy oraz wirusa zakaźnego zapalenia torby Fabrycjusza
MX2020003591A (es) 2017-10-12 2020-07-22 Intervet Int Bv Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
CN109142734B (zh) * 2018-10-26 2021-07-16 北京纳百生物科技有限公司 禽流感病毒H5亚型Re-6株抗体鉴定试剂盒
CN110205308A (zh) * 2019-05-24 2019-09-06 华南农业大学 一种表达ha基因的重组火鸡疱疹病毒及其应用
JP2023506919A (ja) * 2019-12-20 2023-02-20 インターベット インターナショナル ベー． フェー． 多価ｈｖｔベクターワクチン
CA3195621A1 (en) 2020-10-15 2022-04-21 Motoyuki Esaki Recombinant hvt and uses thereof
USD1116120S1 (en) 2021-10-11 2026-03-03 Hydrafacial Llc Skin treatment device
USD1112778S1 (en) 2022-03-04 2026-02-10 Hydrafacial Llc Light therapy device for skin care
USD1084369S1 (en) 2023-02-10 2025-07-15 Hydrafacial Llc Skin treatment tip

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5853733A (en) * 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
US6632664B1 (en) * 1997-10-03 2003-10-14 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
US6410222B1 (en) * 1998-12-14 2002-06-25 Juridical Foundation The Chemosero-Therapeutic Research Institute In ovo vaccination of marek's disease type I virus
US6866852B2 (en) * 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
CN100393870C (zh) * 2003-05-05 2008-06-11 波依斯汤普森植物研究所 用于制备免疫保护性组合物的载体和来源于转基因植物的细胞
EP1924282B1 (en) * 2005-08-15 2017-01-11 Altimmune Inc. Immunization of avians by administration of non-replicating vectored vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUSCHOW ET AL: "Protection of chickens from lethal avian influenza A cirus infetion by live-virus vaccination with infectious larynogotracheitis virus recombinants expressing the hemagglutinin(H5) gene", 《VACCINE》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111733143A (zh) * 2012-03-30 2020-10-02 法国诗华动物保健公司 多价重组禽疱疹病毒和用于免疫禽类的疫苗
CN103740759A (zh) * 2014-01-20 2014-04-23 中国农业科学院哈尔滨兽医研究所 表达h5n1亚型禽流感病毒ha基因的重组火鸡疱疹病毒
CN106399267A (zh) * 2016-10-28 2017-02-15 扬州大学 表达H7N9亚型禽流感病毒血凝素蛋白的重组火鸡疱疹病毒株rHOH及构建方法
CN106497893A (zh) * 2016-10-28 2017-03-15 扬州大学 表达H7N9亚型禽流感病毒嵌合型血凝素蛋白的重组火鸡疱疹病毒株rHMW及构建方法
CN109402071A (zh) * 2018-11-08 2019-03-01 中国农业大学 一种表达h9n2亚型禽流感病毒h9蛋白的重组火鸡疱疹病毒
CN109402071B (zh) * 2018-11-08 2021-04-27 中国农业大学 一种表达h9n2亚型禽流感病毒h9蛋白的重组火鸡疱疹病毒
CN114184797A (zh) * 2021-12-06 2022-03-15 辽宁成大生物股份有限公司 一种流感病毒裂解疫苗单价原液血凝素的检测方法
WO2025180501A1 (en) * 2024-02-29 2025-09-04 Ceva Animal Health Technology (Hangzhou) Co., Ltd. Recombinant hvt and uses thereof

Also Published As

Publication number Publication date
US10072272B2 (en) 2018-09-11
JP5508252B2 (ja) 2014-05-28
JP2010532157A (ja) 2010-10-07
US20100092510A1 (en) 2010-04-15
US20150110835A1 (en) 2015-04-23
EP2129390A4 (en) 2010-09-22
BRPI0809529A2 (pt) 2014-10-14
US20180363006A1 (en) 2018-12-20
ES2399845T3 (es) 2013-04-03
US20080241188A1 (en) 2008-10-02
WO2008121329A3 (en) 2010-04-22
EP2129390B1 (en) 2012-11-21
US8927270B2 (en) 2015-01-06
PL2129390T3 (pl) 2013-06-28
EP2129390A2 (en) 2009-12-09
US10655146B2 (en) 2020-05-19
US20170298386A9 (en) 2017-10-19
WO2008121329A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
CN101903040A (zh) 含有禽流感基因的火鸡疱疹病毒载体重组体
Johnson et al. Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines
Miller et al. Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge
Wesley et al. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus
Lüschow et al. Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene
CN104364381B (zh) 多价重组禽疱疹病毒和用于免疫禽类的疫苗
RU2692013C2 (ru) Улучшенная вакцина против nd-ibd на основе вектора hvt
Li et al. Recombinant herpesvirus of turkeys as a vector-based vaccine against highly pathogenic H7N1 avian influenza and Marek's disease
CN106031793B (zh) 一种活疫苗及其制备方法和应用
JP2023506919A (ja) 多価ｈｖｔベクターワクチン
Rosas et al. Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza
Williams et al. A recombinant bovine herpesvirus-4 vectored vaccine delivered via intranasal nebulization elicits viral neutralizing antibody titers in cattle
MX2011005231A (es) Vacuna recombinante de vector viral inactivado.
Robertson et al. Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines
Choi et al. Preparation and diagnostic utility of a hemagglutination inhibition test antigen derived from the baculovirus-expressed hemagglutinin-neuraminidase protein gene of Newcastle disease virus
Swayne et al. Improvements to the hemagglutination inhibition test for serological assessment of recombinant fowlpox–H5-avian-influenza vaccination in chickens and its use along with an agar gel immunodiffusion test for differentiating infected from noninfected vaccinated animals
Guo et al. The immune enhancement effects of recombinant NDV expressing chicken granulocyte‐macrophage colony‐stimulating factor on the different avian influenza vaccine subtypes
Nišavić et al. Molecular detection of bovine herpesvirus 1 (BoHV-1) in cattle in Serbia
Hwa et al. Characterization of recombinant raccoonpox vaccine vectors in chickens
RU2326943C1 (ru) Способ создания рекомбинантного аденовируса птиц для вакцинации против вируса гриппа птиц н5n1
Moussa et al. Genotyping of recent virulent Newcastle disease virus strains isolated from Menofia governorate, Egypt
Abodalal et al. Efficacy of prepared inactivated Newcastle disease virus vaccine using different oil adjuvants.
De Boer Approaches to control avian lymphoid leukosis
Shahid et al. Infectious Laryngotracheitis Virus: Molecular Biology, Pathobiology, and Control Strategies
Omar et al. EVALUATION OF RECOMBINANT AVIAN INFLUENZA COMPARED TO INACTIVATED VACCINES TO INDUCE IMMUNE RESPONSE IN CHICKEN

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101201